LogoPeqSERPE
logoCabeceraNinos
Última actualización: 11 enero 2022
PUBLICIDAD
 
2026 SERPE Madrid SaveTheDate HULP  imagen vacunación  Imagen Bechi va al cole Cartel webinar Actividades de Formación Avaladas por SERPE
protocolos
Criterios Diagnósticos
Enlaces de interés
Hemos leído
Locomotor
Grupos de Trabajo
Locomotor Descargas
quienesSomos
Grupos de Trabajo
Actividades
Hazte Socio
Sociedades y Congresos
Otros Congresos de interés
Becas y Premios
Sugerencias
Última actualización: 05 marzo 2026
 
ENERO 2026
  • Ata EB, Kılıç L, Fırlatan Yazgan B, Kart Bayram SG, Ekici M, Ünaldı E, et al.
    Use of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry.
    Clin Rheumatol. 2026 Feb;45(2):781-789.
    https://pubmed.ncbi.nlm.nih.gov/41533222/
DICIEMBRE 2025
  • Courel-Ibáñez J, Prieto-Moreno R, Briones-Vozmediano E, Ariza-Vega P, Angevare S, Anton J et al.
    Systematic literature review informing the EULAR points to consider for patient education in physical activity and self-management of pain during transitional care
    Ann Rheum Dis. 2025 Dec;84(12):2115–2127
    https://pubmed.ncbi.nlm.nih.gov/39939275/
NOVIEMBRE 2025

  • Lazarević D, Stamenković H, Stanković T, Đorđević S, Novaković D, Zečević M, et al
    Impact of Biologic Therapy, School Success, Parent's Education and Socioeconomic Status on Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Their Parents.
    Indian Pediatr. 2025 Sep 15. doi: 10.1007/s13312-025-00188-1. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/40952425/

  • Lustig E, Floyd AL Jr, Friedrich EA, Snyder M, Miller VA.
    Adolescent, Parent and Clinician Perspectives on Time Alone in Chronic Illness Visits at a Single Children's Hospital.
    Child Care Health Dev. 2025 Sep;51(5):e70147. doi: 10.1111/cch.70147.
    https://pubmed.ncbi.nlm.nih.gov/40761030/

JULIO 2025

  • El Tal T, Steiman A, Knight A, Hiraki LT, Levy DM, Toulany A, Silverman ED.
    A Pediatric-Adult Provider Dyad Care Model Improves Transition From Pediatric to Adult Healthcare For Youth with Childhood-onset Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Jul 25:jrheum.2025-0046. doi: 10.3899/jrheum.2025-0046. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/40713176/

JUNIO 2025

  • Kulkarni PP, McCrae KR.
    Targeting JAK-STAT in macrophage activation syndrome-no MAS!
    Blood. 2025 Jul 31;146(5):528-530. doi: 10.1182/blood.2025029681.
    https://pubmed.ncbi.nlm.nih.gov/40742725/

  • Wang CY, Lee JH, Lee NC, Hu YC, Chang HH, Wang LC, et al.
    Etiologies and long-term outcome of pediatric hemophagocytic lymphohistiocytosis and macrophage activation syndrome in Taiwan: a single-center retrospective study.
    Front Immunol. 2025 Jul 9;16:1596113. doi: 10.3389/fimmu.2025.1596113.
    https://pubmed.ncbi.nlm.nih.gov/40703525/

 
MARZO 2025

  • De Nardi L, Pastore S, Benaly H, Rispoli F, Giovannini I, Quartuccio L, et al.
    Transition-related outcomes among a cohort of patients with juvenile idiopathic arthritis.
    Clin Rheumatol. 2025 Mar;44(3):1377-1384. doi: 10.1007/s10067-025-07317-y. 
    https://pubmed.ncbi.nlm.nih.gov/39821121/

  • Renson T, Lightstone L, Ciurtin C, Gaymer C, Marks SD.
    The unique challenges of childhood-onset systemic lupus erythematosus and  lupus nephritis patients: a proposed framework for an individualized transitional care plan.
    Pediatr Nephrol. 2025 Mar 13. doi: 10.1007/s00467-024-06654-5. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/40080183/

 
ENERO 2025

  • Chang JC, Alonzi G, Sears C, Bitencourt N, Hernandez A, Peterson R, et al; CARRA Transition Workgroup.
    Transition Guide Dissemination to Foster Patient-Care Team Conversations: A Childhood Arthritis Rheumatology Research Alliance Transition Learning Collaborative Pilot Implementation Study.
    ACR Open Rheumatol. 2025 Jan;7(1):e11753. doi: 10.1002/acr2.11753. Epub 2024 Oct 9.
    https://pubmed.ncbi.nlm.nih.gov/39381857/

  • De Nardi L, Pastore S, Benaly H, Rispoli F, Giovannini I, Quartuccio L, et al.
    Transition-related outcomes among a cohort of patients with juvenile idiopathic arthritis.
    Clin Rheumatol. 2025 Jan 16. doi: 10.1007/s10067-025-07317-y. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39821121/

  • Marrani E, Zajc Avramovic M, Marinello D, Talarico R, Baldini C, Collado-González E, Fonseca JE, Schraven L, Oliveira Ramos F, Triggianese P, Vissink A, Mosca M, Avcin T, Simonini G.
    Challenges in the transition of care for rare connective tissue diseases: results from the 2023 ERN ReCONNET Transition of Care Task Force survey.
    Rheumatol Adv Pract. 2025 Jan 11;9(1):rkae149. doi: 10.1093/rap/rkae149.
    https://pubmed.ncbi.nlm.nih.gov/39886538/

DICIEMBRE 2024

  • Fan J, Hao J, Fu Y, Liu X, Qu HQ, Glessner JT et al.
    Genetic Association of Juvenile Idiopathic Arthritis With Adult Rheumatic Disease.
    JAMA Netw Open. 2024 Dec 2;7(12):e2451341. doi: 10.1001/jamanetworkopen.2024.51341.
    https://pubmed.ncbi.nlm.nih.gov/39729320/

  • Şahin N, Baykal GÖ, Açarı C, Aydın PÖA, Baba Ö, Bağlan E et al.
    Consensus on transition care for juvenile idiopathic arthritis: a Delphi study with youth, caregivers, and health professionals.
    Pediatr Rheumatol Online J. 2024 Dec 18;22(1):105. doi: 10.1186/s12969-024-01047-2.
    https://pubmed.ncbi.nlm.nih.gov/39695685/

  • Nishat F, Kelenc L, Berard R, Duffy C, Feldman B, Forgeron P et al.
    Assessing the impact of the iPeer2Peer program for adolescents with juvenile idiopathic arthritis: a mixed-methods randomized controlled trial.
    Pediatr Rheumatol Online J. 2024 Dec 27;22(1):109. doi: 10.1186/s12969-024-01052-5.
    https://pubmed.ncbi.nlm.nih.gov/39731098/

  • Israni M, Alderson E, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H et al.
    Recommendations for Transitioning Young People with Primary Immunodeficiency Disorders and Autoinflammatory Diseases to Adult Care.
    J Clin Immunol. 2024 Dec 17;45(1):57. doi: 10.1007/s10875-024-01838-y.
    https://pubmed.ncbi.nlm.nih.gov/39690292/

  • Celli L, Garrelfs MR, Sakkers RJB, Elting MW, Celli M, Bökenkamp A et al.
    Adapting to Adulthood: A Review of Transition Strategies for Osteogenesis Imperfecta.
    Calcif Tissue Int. 2024 Dec;115(6):960-975. doi: 10.1007/s00223-024-01305-1. Epub 2024 Nov 13.
    https://pubmed.ncbi.nlm.nih.gov/39535563/

NOVIEMBRE 2024

  • Courel-Ibáñez J, Prieto-Moreno R, Briones-Vozmediano E, Ariza-Vega P, Angevare S, Anton J, Bini I, Clemente D, Correia M, Costello W, De Cock D, Domján A, Leon L, Marques A, Minden K, Mourão AF, Najm A, Ozen S, Pimentel G, Saleem Z, Vetrovsky T, Wulffraat NM, Zacarias Crovato A, Prior Y, Carmona L, Estévez-López F.
    EULAR points to consider for patient education in physical activity and self-management of pain during transitional care.
    Ann Rheum Dis. 2024 Nov 11:ard-2024-226448. doi: 10.1136/ard-2024-226448. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39532311/

OCTUBRE 2024

  • Argraves M, Murray E, Taxter A, Wise K, Jensen PT, Goldstein-Leever A, Thomas B, Scott A, Gallup J, Leone A, Ardoin SP, Sivaraman V.
    Implementation of an automated transition readiness assessment in a pediatric rheumatology clinic.
    Front Pediatr. 2024 Oct 17;12:1457651. doi: 10.3389/fped.2024.1457651. eCollection 2024
    https://pubmed.ncbi.nlm.nih.gov/39483530/

  • Haney H, Klotsche J, Niewerth M, Hansmann S, Erbis G, Reiser C, Saur SJ, Hoff P, Seipelt E, Maier A, Schalm S, Tatsis S, Foeldvari I, Kötter I, Minden K.
    Assessing Competencies, Needs, and Satisfaction With the Transition From Pediatric to Adult Health Care in Rheumatology: Development and Validation of the Transition-KompAZ
    J Rheumatol. 2024 Oct 1;51(10):1048. doi: 10.3899/jrheum.2024-0097.C1.
    https://pubmed.ncbi.nlm.nih.gov/39227058/

SEPTIEMBRE 2024

  • Oliveira Ramos F, Carolina Zinterl C, Fonseca JE
    A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis
    Best Pract Res Clin Rheumatol 2024 Sep;38(3):101984. doi: 10.1016/j.berh.2024.101984.
    https://pubmed.ncbi.nlm.nih.gov/39068102/

AGOSTO 2024

  • Ariane A, Oey C, Sumariyono S, Herqutanto H, Kurniati N, Hidayat R, Shatri H.
    Autoimmune rheumatic transitional care model development.
    BMC Rheumatol. 2024 Aug 29;8(1):38. doi: 10.1186/s41927-024-00407-5.
    https://pubmed.ncbi.nlm.nih.gov/39210482/

  • Inoue Y, Sakai R, Inoue E, Mitsunaga K, Shimizu M, Sugihara T, et al.
    Nationwide epidemiological survey of juvenile idiopathic arthritis during transition to young adulthood in Japan using the National Database of Designated Incurable Diseases of Japan.
    Mod Rheumatol. 2024 Aug 22:roae076. doi: 10.1093/mr/roae076.
    https://pubmed.ncbi.nlm.nih.gov/39172631/

  • Elhani I, Hentgen V, Quartier P, Bader-Meunier B, Kone-Paut I, Neven B, et al.
    Transition to Adult Care in Autoinflammatory Diseases: A Cohort of 111 French Patients.
    J Clin Rheumatol. 2024 Aug 26. doi: 10.1097/RHU.0000000000002132.
    https://pubmed.ncbi.nlm.nih.gov/39186594/

JUNIO 2024

  • Cintron D, Chang JC, Sadun RE.
    Transition to Adult Rheumatology Care: A Disease-Specific Guide.
    J Clin Rheumatol. 2024 Jun 1;30(4):159-167. doi: 10.1097/RHU.0000000000002062.
    https://pubmed.ncbi.nlm.nih.gov/38527973/ 

MARZO 2024

  • Vermé A, Wenemark M, Jungner JG, Broström E, Bartholdson C.
    Ready to leave? - Adolescents' and parents' perceptions of transition from paediatric to adult rheumatology care.
    BMC Health Serv Res. 2024 Jul 10;24(1):795. doi: 10.1186/s12913-024-11265-9.
    https://pubmed.ncbi.nlm.nih.gov/38987769/

  • Heera S, Beattie K, Punthakee Z, DiRezze B, Herrington J, Cellucci T, et al.
    The TRUST Study-TRansition US Together: Evaluating the Impact of a Parent- and Adolescent-Centered Transition Toolkit on Transition Readiness in Patients with Juvenile Idiopathic Arthritis and Childhood-Onset Systemic Lupus Erythematosus.
    Children (Basel). 2024 Jul 20;11(7):881. doi: 10.3390/children11070881.
    https://pubmed.ncbi.nlm.nih.gov/39062330/

MARZO 2024

  • Huynh A, Buckle J, Cox A, Czerniecki L, Gowdie P, Renton W, et al.
    The transition process for paediatric rheumatology clinic patients at a single tertiary paediatric rheumatology centre in Australia.
    J Paediatr Child Health. 2024 May 19. doi: 10.1111/jpc.16563. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38764198/

MARZO 2024

  • Arons A, Tsevat RK, Hotez E, Huang H, Nott R, Ahn H, et al
    A Quality Improvement Initiative to Improve Health Care Transition Planning at Adolescent Well Visits.
    Acad Pediatr. 2024 Mar 20:S1876-2859(24)00112-8. doi: 10.1016/j.acap.2024.03.013. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38519016/

 
FEBRERO 2024

  • Choukair D, Patry C, Lehmann R, Treiber D, Hoffmann GF, Grasemann C, et al.
    Resource utilization and costs of transitioning from pediatric to adult care for patients with chronic autoinflammatory and autoimmune disorders.
    Pediatr Rheumatol Online J. 2024 Feb 23;22(1):28. doi: 10.1186/s12969-024-00963-7.
    https://pubmed.ncbi.nlm.nih.gov/38395977/

 
SEPTIEMBRE 2023

  • Şahin N, Sönmez HE, Aktay Ayaz N, Sözeri B.
    Addressing the unmet needs of transitional care in juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2023 Sep 29:kead518. doi: 10.1093/rheumatology/kead518. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37774006/

 
AGOSTO 2023

  • Dushnicky MJ, Fine C, Cellucci T, Garner S, Heale L, Matsos M, Beattie KA, Batthish M.
    Mind the Gap: A Longitudinal Analysis of the Experiences of Adolescents and Parents in a Rheumatology Transition Clinic
    J Clin Rheumatol. 2023 Aug 1;29(5):235-239. doi: 10.1097/RHU.0000000000001988. Epub 2023 May 25.
    https://pubmed.ncbi.nlm.nih.gov/37221634/

JULIO 2023

  • Felis-Giemza A, Chmurzyńska K, Kołodziejczyk B, Gazda A.
    Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study.
    Rheumatol Int. 2023 Jul;43(7):1307-1311. doi: 10.1007/s00296-023-05293-7.
    https://pubmed.ncbi.nlm.nih.gov/36859560/

  • de Sonnaville WFC, Speksnijder CM, Zuithoff NPA, Heijstek MW, Wulffraat NM, Steenks MH, Rosenberg AJWP.
    Clinically Established Temporomandibular Involvement in Adults With Juvenile Idiopathic Arthritis.
    J Rheumatol. 2023 Jul 1:jrheum.2023-0204. doi: 10.3899/jrheum.2023-0204. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37399466/

 
 
JUNIO 2023

  • Dushnicky MJ, Fine C, Cellucci T, Garner S, Heale L, Matsos M, Beattie KA, Batthish M.
    Mind the Gap: A Longitudinal Analysis of the Experiences of Adolescents and Parents in a Rheumatology Transition Clinic.
    J Clin Rheumatol. 2023 May 24. doi: 10.1097/RHU.0000000000001988. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37221634/

 
MARZO 2023

  • Teh KL, Hoh SF, Chan SB, Gao X, Das L, Book YX, Arkachaisri T.
    Experience of an Asian paediatric rheumatology transition programme: high success rate with the use of transition readiness assessment tool.
    Singapore Med J. 2023 Mar 24. doi: 10.4103/singaporemedj.SMJ-2021-279. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37026359/

  • Ross J, Bowden MR, Yu C, Diaz-Thomas A.
    Transition of young adults with metabolic bone diseases to adult care.
    Front Endocrinol (Lausanne). 2023 Mar 17;14:1137976. doi: 10.3389/fendo.2023.1137976.
    https://pubmed.ncbi.nlm.nih.gov/37008909/

 
ENERO 2023

  • Israni M, Nicholson B, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, et al; RITA-ERN Transition Working Group Consortium.
    Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.
    J Clin Immunol. 2023 Jan;43(1):206-216. doi: 10.1007/s10875-022-01345-y. Epub 2022 Oct 12.
    https://pubmed.ncbi.nlm.nih.gov/36222999/

  • Smitherman EA, Chahine RA, Bitencourt N, Rahman AKMF, Lawson EF, Chang JC; CARRA Registry Investigators and CARRA Transition Workgroup.
    Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    J Rheumatol. 2023 Jan;50(1):98-106. doi: 10.3899/jrheum.220514. Epub 2022 Sep 15.
    https://pubmed.ncbi.nlm.nih.gov/36109074/

DICIEMBRE 2022

  • Boeker LS, Kuemmerle-Deschner JB, Saur SJ, Klotsche J, Erbis G, Hansmann S.
    Health-related quality of life, continuity of care and patient satisfaction: long-term outcomes of former patients of the Tuebingen Transition Program (TTP) - a retrospective cohort study
    Pediatr Rheumatol Online J. 2022 Dec 27;20(1):121. doi: 10.1186/s12969-022-00776-6.
    https://pubmed.ncbi.nlm.nih.gov/36575486/

  • Thomsen EL, Boisen KA, Hanghøj S, Hansson H, Grabow Scheelhardt HV, Christensen ST, Esbensen BA.
    A comprehensive transfer program from pediatrics to adult care for parents of adolescents with chronic illness (ParTNerSTEPs): study protocol for a randomized controlled trial
    Trials. 2022 Dec 20;23(1):1034. doi: 10.1186/s13063-022-06997-0.
    https://pubmed.ncbi.nlm.nih.gov/36539857/

NOVIEMBRE 2022

  • Currie GR, Harris M, McClinton L, Trehan N, Van Dusen A, Shariff M, Kuzmyn T, Marshall DA.
    Transitions from pediatric to adult rheumatology care for juvenile idiopathic arthritis: a patient led qualitative study.
    BMC Rheumatol. 2022 Nov 14;6(1):85. doi: 10.1186/s41927-022-00316-5.
    https://pubmed.ncbi.nlm.nih.gov/36376987/

  • Bitencourt N, Lawson E, Bridges J, Carandang K, Chintagunta E, Chiraseveenuprapund P, et al.
    Pediatric to Adult Transition Literature: Scoping Review and Rheumatology Research Prioritization Survey Results.
    J Rheumatol. 2022 Nov;49(11):1201-1213. doi: 10.3899/jrheum.220262.
    https://pubmed.ncbi.nlm.nih.gov/35914787/

 
OCTUBRE 2022

  • Israni M, Nicholson B, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, et al; RITA-ERN Transition Working Group Consortium.
    Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.
    J Clin Immunol. 2022 Oct 12. doi: 10.1007/s10875-022-01345-y. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/36222999/

  • Mikola K, Rebane K, Arnstad ED, Berntson L, Fasth A, Glerup M, Herlin T, Kautiainen H, Nielsen S, Nordal E, Peltoniemi S, Rygg M, Rypdal V, Zak M, Aalto K.
    Transitioning patients with juvenile idiopathic arthritis to adult care: the Nordic experience.
    Pediatr Rheumatol Online J. 2022 Oct 1;20(1):84. doi: 10.1186/s12969-022-00742-2.
    https://pubmed.ncbi.nlm.nih.gov/36182898/

  • Roberts JE, Halyabar O, Petty CR, Alfieri M, Esty B, Dallas J, Hazen M, Stein S, Son MBF.
    Longitudinal assessment of preparation for care transition among adolescents and young adults with rheumatologic disease: a single-center pilot study.
    Pediatr Rheumatol Online J. 2022 Oct 21;20(1):93. doi: 10.1186/s12969-022-00751-1.
    https://pubmed.ncbi.nlm.nih.gov/36271446/

 
AGOSTO 2022

  • Bitencourt N, Lawson E, Bridges J, Carandang K, Chintagunta E, Chiraseveenuprapund P, DeQuattro K, Goh YI, Lee TC, Moore KF, Peterson RG, Roberts JE, Ronis T, Sadun RE, Smitherman EA, Stringer E, White PH, Chang JC; CARRA Transition Workgroup.
    Pediatric to Adult Transition Literature: Scoping Review and Rheumatology Research Prioritization Survey Results
    J Rheumatol. 2022 Aug 1:jrheum.220262. doi: 10.3899/jrheum.220262. 
    https://pubmed.ncbi.nlm.nih.gov/35914787/

  • Ma C, Dushnicky M, Talaat H, Thomas S, Cellucci T, Garner S, Heale L, Matsos M, Beattie K, Batthish M.
    Self-Reported Transition Readiness of Adolescent Patients with Rheumatic Disease: Do the Parents Agree?
    J Pediatr. 2022 Aug;247:155-159. doi: 10.1016/j.jpeds.2022.05.009. Epub 2022 May 11.
    https://pubmed.ncbi.nlm.nih.gov/35561803/

 
JULIO 2022

  • Carandang K, Wells CK, Guglielmo D, Melcher K, Trimble M, Ardoin SP, Chira P.
    Adolescents' and Young Adults' Recommendations for Implementing Healthcare Transition in Rheumatology: A Mixed Methods Study.
    Arthritis Care Res (Hoboken). 2022 Jun 30. doi: 10.1002/acr.24977. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35771592/

 
JUNIO 2022

  • Ciosek AL, Makris UE, Kramer J, Bermas BL, Solow EB, Wright T, Bitencourt N.
    Health Literacy and Patient Activation in the Pediatric to Adult Transition in Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives.
    ACR Open Rheumatol. 2022 Jun 18. doi: 10.1002/acr2.11474. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35716025/

MAYO 2022

  • Mulla I, Yeung RSM, Noone DG, Bell-Peter A, Pagnoux C.
    Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.
    Clin Exp Rheumatol. 2022 May;40(4):772-778. doi: 10.55563/clinexprheumatol/uhsrnm.
    https://pubmed.ncbi.nlm.nih.gov/35238755/

MARZO 2022

  • Mikola K, Rebane K, Glerup M, Kautiainen H, Relas H, Peltoniemi S, Aalto K.
    Transition to adult care in Finnish adolescents with juvenile idiopathic arthritis.
    Scand J Rheumatol. 2022 Mar 11:1-5. doi: 10.1080/03009742.2022.2040117. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35272583/

FEBRERO 2022

  • García-Rodríguez F, Raygoza-Cortez K, Moreno-Hernandez L, García-Pérez R, Garza Lopez LE, Arana-Guajardo AC, Jáquez-Quintana JO, Villarreal-Treviño AV, de la O-Cavazos ME, Rubio-Pérez N.
    Outcomes of transitional care programs on adolescent chronic inflammatory systemic diseases: systematic review and meta-analyses.
    Pediatr Rheumatol Online J. 2022 Feb 17;20(1):15. doi: 10.1186/s12969-022-00670-1.
    Https://pubmed.ncbi.nlm.nih.gov/35177101/

  • Mori M, Akioka S, Igarashi T, Inoue Y, Umebayashi H, Ohshima S, Nishiyama S, Hashimoto M, Matsui T, Miyamae T, Yasumi T.
    Transitioning from paediatric to adult rheumatological healthcare: English summary of the Japanese Transition Support Guide.
    Mod Rheumatol. 2022 Feb 28;32(2):248-255. doi: 10.1093/mr/roab071.
    https://pubmed.ncbi.nlm.nih.gov/34918115/

  • Teh KL, Hoh SF, Arkachaisri T.
    The Coming-of-Age Transition Care for Adolescents with Rheumatic Disease-Where Are We and What Have We Done in Asia?
    J Clin Med. 2021 Feb 17;10(4):821. doi: 10.3390/jcm10040821.
    https://pubmed.ncbi.nlm.nih.gov/33671413/

  • Mulla I, Yeung RSM, Noone D, Bell-Peter A, Pagnoux C.
    Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.
    Clin Exp Rheumatol. 2022 Feb 28. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35238755/

 
DICIEMBRE 2021

  • Overbury RS, Huynh K, Bohnsack J, Frech T, Hersh A.
    A novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes.
    Pediatr Rheumatol Online J. 2021 Dec 1;19(1):164. doi: 10.1186/s12969-021-00651-w.
    https://pubmed.ncbi.nlm.nih.gov/34852832/

  • Bitencourt N, Ciosek A, Kramer J, Blair Solow E, Bermas B, Wright T, Nassi L, Makris U.
    "You Just Have to Keep Going, You Can't Give Up": Coping mechanisms among young adults with lupus transferring to adult care.
    Lupus. 2021 Dec;30(14):2221-2229. doi: 10.1177/09612033211061057. Epub 2021 Dec 7.
    https://pubmed.ncbi.nlm.nih.gov/34874764/

NOVIEMBRE 2021

  • Oliveira Ramos F, Rodrigues A, Magalhaes Martins F, Melo AT, Aguiar F, Brites L, Azevedo S, Duarte AC, Furtado C, Mourão AF, Sequeira G, Cunha I, Figueira R, Melo Gomes JA, Santos MJ, Fonseca JE.
    Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases.
    RMD Open. 2021 Nov;7(3):e001766. doi: 10.1136/rmdopen-2021-001766
    https://pubmed.ncbi.nlm.nih.gov/34819385/

  • Chang JC, Sears C, Bitencourt N, Peterson R, Alperin R, Goh YI, Overbury RS, Sadun R, Smitherman E, White PH, Lawson EF, Carandang K; CARRA Transition Workgroup.
    Implementation of rheumatology health care transition processes and adaptations to systems under stress: a mixed methods study.
    Arthritis Care Res (Hoboken). 2021 Nov 21. doi: 10.1002/acr.24822. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34806346/ 

SEPTIEMBRE 2021

  • Tan J, Tiller G, Gowdie P, Cox A, Munro J, Allen R, Akikusa J.
    Patterns and rates of confirmed transfer of care of patients with Juvenile Idiopathic Arthritis at a tertiary paediatric rheumatology centre.
    Intern Med J. 2021 Sep 8. doi: 10.1111/imj.15509. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34498355/

 
AGOSTO 2021

  • McDonagh JE, Tattersall R, Clinch J, Swan J, Foster HE, McCann L.
    Developmentally appropriate transitional care during the Covid-19 pandemic for young people with juvenile-onset rheumatic and musculoskeletal diseases: the rationale for a position statement.
    Pediatr Rheumatol Online J. 2021 Aug 25;19(1):136. doi: 10.1186/s12969-021-00609-y.
    https://pubmed.ncbi.nlm.nih.gov/34433477/

JUNIO 2021

  • Lynn Spiegel, Lori Tucker et al.
    Development and validation of the RACER (Readiness for Adult Care in Rheumatology) transition instrument in youth with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2021 Jun 5;19(1):83. doi: 10.1186/s12969-021-00579-1.
    https://pubmed.ncbi.nlm.nih.gov/34090474/

 
MAYO 2021

  • Stephens SB, Raphael JL, Zimmerman CT, Garland BH, de Guzman MM, Walsh SM, Hergenroeder AC, Wiemann CM.
    The Utility of Self-Determination Theory in Predicting Transition Readiness in Adolescents With Special Healthcare Needs.
    J Adolesc Health 2021 May 28:S1054-139X(21)00197-X. doi:10.1016/j.jadohealth.2021.04.004.
    Epub ahead of print. PMID: 34059429.
    https://pubmed.ncbi.nlm.nih.gov/34059429/

  •  Roberts JE, Halyabar O, Petty CR, Son MB.
    Assessing preparation for care transition among adolescents with rheumatologic disease: a single-center assessment with patient survey.
    Pediatr Rheumatol Online J. 2021 May 1;19(1):61. doi:10.1186/s12969-021-00544-y
    https://pubmed.ncbi.nlm.nih.gov/33933123/

MARZO 2021

  • McColl J, Semalulu T, Beattie KA, Alam A, Thomas S, Herrington J, Gorter JW, Cellucci T, Garner S, Heale L, Matsos M, Batthish M.
    Transition Readiness in Adolescents With Juvenile Idiopathic Arthritis and Childhood-Onset Systemic Lupus Erythematosus.
    ACR Open Rheumatol. 2021 Mar 12. doi: 10.1002/acr2.11237. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33711192/

  • Sönmez HE, Koç R, Karadağ ŞG, Aktay Ayaz N.
    The readiness of pediatric rheumatology patients and their parents to transition to adult-oriented treatment.
    Int J Rheum Dis. 2021 Mar;24(3):397-401. doi: 10.1111/1756-185X.14050.
    https://pubmed.ncbi.nlm.nih.gov/33452739/

 
FEBRERO 2021
ENERO 2021

  • Sönmez HE, Koç R, Karadağ ŞG, Aktay Ayaz N.
    The readiness of pediatric rheumatology patients and their parents to transition to adult-oriented treatment.
    Int J Rheum Dis. 2021 Jan 15. doi: 10.1111/1756-185X.14050. Epub ahead of print. PMID: 33452739.
    https://pubmed.ncbi.nlm.nih.gov/33452739/

  • de Oliveira RJ, Kishimoto ST, de Souza DP, Fernandes PT, Marini R, Appenzeller S.
    The importance of transition from pediatric to adult rheumatology care in juvenile idiopathic arthritis.
    Expert Rev Clin Immunol. 2021 Jan 22:1-7. doi: 10.1080/1744666X.2020.1865157. Epub ahead of print. PMID: 33393405.
    https://pubmed.ncbi.nlm.nih.gov/33393405/

OCTUBRE 2020

  • Barnabe C, Chomistek K, Luca N, Hazlewood G, Barber CEH, Steiman A, Stringer E.
    National Priorities for High Quality Rheumatology Transition Care for Youth in Canada.
    J Rheumatol. 2020 Oct 15:jrheum.200790. doi: 10.3899/jrheum.200790. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33060318/

SEPTIEMBRE 2020

  • Bitencourt N, Kramer J, Bermas BL, Solow EB, Wright T, Makris UE.
    Clinical Team Perspectives on the Psychosocial Aspects of Transition to Adult Care for Patients with Childhood-Onset Systemic Lupus Erythematosus.
    Arthritis Care Res (Hoboken). 2020 Sep 25. doi: 10.1002/acr.24463. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32976698/

  • García-Fernández A, Gerardi MC, Crisafulli F, Filippini M, Fredi M, Gorla R, Lazzaroni MG, Lojacono A, Nalli C, Ramazzotto F, Taglietti M, Zanardini C, Zatti S, Franceschini F, Tincani A, Andreoli L.
    Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic.
    Clin Rheumatol. 2020 Sep 18. doi: 10.1007/s10067-020-05404-w. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32945981/

 
AGOSTO 2020

  • Matsumoto T, Mori M.
    Questionnaire survey on transitional care for patients with juvenile idiopathic arthritis (JIA) and families.
    Mod Rheumatol. 2020 Aug 24:1-18. doi: 10.1080/14397595.2020.1813369.
    https://pubmed.ncbi.nlm.nih.gov/32838644/

JULIO 2020

  • Haro SL, Lawson EF, Hersh AO.
    Disease activity and health-care utilization among young adults with childhood-onset lupus transitioning to adult care: data from the Pediatric Lupus Outcomes Study.
    Lupus. 2020 Jul 8:961203320938868. doi: 10.1177/0961203320938868. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32640935/

  • Chauveau S, Jeny F, Montagne ME, Taam RA, Houdouin V, Meinzer U, Delacourt C, Epaud R, Aubart FC, Chapelon-Abric C, Israël-Biet D, Juvin K, Dossier A, Bodaghi B, Prévot G, Naccache JM, Mattioni S, Deschildre A, Brouard J, Tazi A, Meckenstock R, Didier M, Haroche J, Clement A, Bernaudin JF, Nunes H, Valeyre D, Nathan N, Gsf FTFSG.
    Child-Adult Transition in Sarcoidosis: A Series of 52 Patients.
    J Clin Med. 2020 Jul 3;9(7):E2097. doi: 10.3390/jcm9072097.
    https://pubmed.ncbi.nlm.nih.gov/32635292/

 
MAYO 2020
  • Kelly A, Niddrie F, Tunnicliffe DJ, Matus Gonzalez A, Hanson C, Jiang I, Major G, Singh-Grewal D, Tymms K, Tong A.
    Patients' attitudes and experiences of transition from paediatric to adult healthcare in rheumatology: a qualitative systematic review.
    Rheumatology (Oxford). 2020 May 15:keaa168.
    https://doi.org/10.1093/rheumatology/keaa168
  • Verma T, Rohan J.
    Examination of Transition Readiness, Medication Adherence, and Resilience in Pediatric Chronic Illness Populations: A Pilot Study.
    Int J Environ Res Public Health. 2020 Mar 15;17(6). pii: E1905. 
    https://www.ncbi.nlm.nih.gov/pubmed/32183424
 
MARZO 2020
  • Verma T, Rohan J.
    Examination of Transition Readiness, Medication Adherence, and Resilience in Pediatric Chronic Illness Populations: A Pilot Study.
    Int J Environ Res Public Health. 2020 Mar 15;17(6). pii: E1905. 
    https://www.ncbi.nlm.nih.gov/pubmed/32183424
 
FEBRERO 2020
  • Chang JC, Knight AM, Lawson EF.
    Patterns of Health Care Utilization and Medication Adherence Among Youth with Systemic Lupus Erythematosus During Transfer from Pediatric to Adult Care.
    J Rheumatol. 2020 Feb 1. pii: jrheum.191029. doi: 10.3899/jrheum.191029.
    https://www.ncbi.nlm.nih.gov/pubmed/32007936
  • Sadun RE.
    Mind the Gap: Improving Care in Pediatric-to Adult Rheumatology Transition Through Education.
    Rheum Dis Clin North Am. 2020 Feb;46(1):103-118. doi: 10.1016/j.rdc.2019.09.008.
    https://www.ncbi.nlm.nih.gov/pubmed/31757279
  • Zisman D, Samad A, Ardoin SP, Chira P, White P, Lavi I, von Scheven E, Lawson EF, Hing M, Mellins ED.
    US Adult Rheumatologists' Perspective on the Transition Process for Young Adults with Rheumatic Conditions.
    Arthritis Care Res (Hoboken). 2019 Feb 11. doi: 10.1002/acr.23845. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30740937
 
OCTUBRE 2018
  • Relas H, Kosola S.
    Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease
    Clin Rheumatol. 2018 Oct 29. doi: 10.1007/s10067-018-4351-4. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30374749
 
AGOSTO 2018
  • Walter M, Kamphuis S, van Pelt P, de Vroed A, Hazes JMW.
    Successful implementation of a clinical transition pathway for adolescents with juvenile-onset rheumatic and musculoskeletal diseases.
    Pediatr Rheumatol Online J. 2018 Aug 3;16(1):50. doi: 10.1186/s12969-018-0268-3.
    https://www.ncbi.nlm.nih.gov/pubmed/30075795
  • Lazaroff SM, Meara A, Tompkins MK, Peters E, Ardoin SP.
    How Do Health Literacy, Numeric Competencies, and Patient Activation Relate to Transition Readiness in Adolescents and Young Adults with Rheumatic Diseases?
    Arthritis Care Res (Hoboken). 2018 Aug 29. doi: 10.1002/acr.23739. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30156761
 
JULIO 2018
  • Sabbagh S, Ronis T, White PH.
    Pediatric rheumatology: addressing the transition to adult-orientated health care.
    Open Access Rheumatol. 2018 Jul 3;10:83-95. doi: 10.2147/OARRR.S138370. eCollection 2018.
    https://www.ncbi.nlm.nih.gov/pubmed/30013406
  • Akre C, Suris JC, Belot A, Couret M, Dang TT, Duquesne A, Fonjallaz B, Georgin-Lavialle S, Larbre JP, Mattar J, Meynard A, Schalm S, Hofer M.
    Building a transitional care checklist in rheumatology: A Delphi-like survey.
    Joint Bone Spine. 2018 Jul;85(4):435-440. doi: 10.1016/j.jbspin.2017.09.003. Epub 2017 Sep 28.
    https://www.ncbi.nlm.nih.gov/pubmed/28965941
 
ABRIL 2018
  • Conti F, Pontikaki I, D'Andrea M, Ravelli A, De Benedetti F.
    Patients with juvenile idiopathic arthritis become adults: the role of transitional care.
    Clin Exp Rheumatol. 2018 Apr 13. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29652654
 
ENERO 2018
  • van Pelt PA, Dolhain RJEM, Kruize AA, Ammerlaan JJW, Hazes JW, Bijlsma JWJ, Wulffraat NM.
    Disease activity and dropout in young persons with juvenile idiopathic arthritis in transition of care: a longitudinal observational study.
    Clin Exp Rheumatol. 2018 Jan-Feb;36(1):163-168.
    https://www.ncbi.nlm.nih.gov/pubmed/29461957
Última actualización: 05 marzo 2026
 
Hemos leído...
DICIEMBRE 2025
  • Li S, Wu X, Jing S, Yang X, Zhang Y, Dong L
    Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis
    Front Pediatr. 2025 Dec 5;13:1695770. doi: 10.3389/fped.2025.169577
    https://pubmed.ncbi.nlm.nih.gov/41425880/
  • Erkens RGA, Rogani G, Huber L, Verwoerd A, Schonenberg-Meinema D, van den Berg JM et al.
    Impact of Interleukin-1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria
    Arthritis Rheumatol. 2025 Dec;77(12):1784–1798
    https://pubmed.ncbi.nlm.nih.gov/40420428/
 
OCTUBRE 2025

  • Schmutz M, Cognard J, Hadchouel A, Berteloot L, Hentgen V, Pietrement C, et al.
    Allogeneic hematopoietic stem cell transplantation for severe Still's disease: a retrospective report of 3 pediatric patients.
    Rheumatology (Oxford). 2025 Sep 1:keaf416. doi: 10.1093/rheumatology/keaf416. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/40889280/

  • De Matteis A, Pardeo M, Caiello I, Matteo V, Marafon DP, Sacco E, et al.
    çTraditional laboratory parameters and IFNγ-related biomarkers in the diagnosis and management of MAS.
    Semin Arthritis Rheum. 2025 Oct;74:152812. doi: 10.1016/j.semarthrit.2025.152812.
    https://pubmed.ncbi.nlm.nih.gov/40845734/

JULIO 2025

  • Kulkarni PP, McCrae KR.
    Targeting JAK-STAT in macrophage activation syndrome-no MAS!
    Blood. 2025 Jul 31;146(5):528-530. doi: 10.1182/blood.2025029681.
    https://pubmed.ncbi.nlm.nih.gov/40742725/

  • Wang CY, Lee JH, Lee NC, Hu YC, Chang HH, Wang LC, et al.
    Etiologies and long-term outcome of pediatric hemophagocytic lymphohistiocytosis and macrophage activation syndrome in Taiwan: a single-center retrospective study.
    Front Immunol. 2025 Jul 9;16:1596113. doi: 10.3389/fimmu.2025.1596113.
    https://pubmed.ncbi.nlm.nih.gov/40703525/

 
JUNIO 2025

  • Xie W, Liu Q, Tang Y, Li Y, Zhang Y, Wang S, Wang L.
    Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China.
    Clin Rheumatol. 2025 Jun;44(6):2087-2093. doi: 10.1007/s10067-025-07465-1.
    https://pubmed.ncbi.nlm.nih.gov/40338417/

MARZO 2025

  • Iosim S, Henderson LA.
    Macrophage Activation Syndrome: Not Just for Rheumatologists Anymore.
    Hematol Oncol Clin North Am. 2025 Mar 24:S0889-8588(25)00019-X. doi: 10.1016/j.hoc.2025.02.004. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/40133144/

  • Inguscio G, Romano S, Mastrolia MV, Simonini G, Giani T.
    Macrophage Activation Syndrome in Kawasaki Disease: Insights from a Systematic Literature Review on Diagnosis, Clinical Features, and Treatment.
    Children (Basel). 2025 Mar 11;12(3):349. doi: 10.3390/children12030349.
    https://pubmed.ncbi.nlm.nih.gov/40150630/

  • Faggioli P, Galeazzi M, Ferrari C, Capelli F, Marchesi C, Marchionni L, et al.
    Macrophage activation syndrome successfully treated with eculizumab and emapalumab: a case report.
    Front Immunol. 2025 Mar 24;16:1555415. doi: 10.3389/fimmu.2025.1555415. 
    https://pubmed.ncbi.nlm.nih.gov/40196116/

  • Lam MT, Jiang CL, Lee PY.
    T-ing up the storm: pathogenic cycling lymphocytes in the biology of macrophage activation syndrome.
    Pediatr Rheumatol Online J. 2025 Mar 17;23(1):29. doi: 10.1186/s12969-025-01081-8.
    https://pubmed.ncbi.nlm.nih.gov/40098189/

FEBRERO 2025

  • Brossard P.
    Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis.
    Clin Transl Sci. 2025 Feb;18(2):e70163.
    https://pubmed.ncbi.nlm.nih.gov/39943917/

  • Basaran O, Sag E, Aydın EA, Aydın B, Tasdemir NK, Celikel E, Bayındır Y, Özdel S, Bilginer Y, Grom AA, Ozen S.
    Lack of HLH in FMF.
    Pediatr Rheumatol Online J. 2025 Feb 8;23(1):14.
    https://pubmed.ncbi.nlm.nih.gov/39923056/

ENERO 2025

  • Baldo F, Erkens RGA, Mizuta M, Rogani G, Lucioni F, Bracaglia C, et al; PReS MAS/sJIA Working Party and Paediatric Rheumatology International Trial Organization.
    Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.
    Rheumatology (Oxford). 2025 Jan 1;64(1):32-44. doi: 10.1093/rheumatology/keae391.
    https://pubmed.ncbi.nlm.nih.gov/39058514/

  • Qian Y, Lu M, Zheng Q.
    IL-10 and IFN-γ as markers for early recognition of pediatric systemic lupus erthematosus complicated with macrophage activation syndrome.
    Rheumatology (Oxford). 2025 Jan 1;64(1):235-241. doi: 10.1093/rheumatology/kead678.
    https://pubmed.ncbi.nlm.nih.gov/38109672/

DICIEMBRE 2024

  • Irabu H, Kaneko S, Miyaoka F, Tomomasa D, Shimbo A, Nishimura A et al.
    Yang and Ying of ruxolitinib administration for macrophage activation syndrome complicated by systemic juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2024 Dec 4:keae656. doi: 10.1093/rheumatology/keae656. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39656844/

NOVIEMBRE 2024

  • Nigrovic PA.
    Macrophage Activation Syndrome
    Arthritis Rheumatol. 2024 Nov 3. doi: 10.1002/art.43052. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39491365/

  • Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F.
    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
    Ann Rheum Dis. 2024 Nov 14;83(12):1731-1747. doi: 10.1136/ard-2024-225854.
    https://pubmed.ncbi.nlm.nih.gov/39317415/

  • Song Z, Yao H, Jin Y, Li X, Jia Y, He J, Li Z.
    Ruxolitinib as a salvage therapy in adult-onset macrophage activation syndrome: insights from eight cases.
    Ann Rheum Dis. 2024 Nov 14;83(12):1798-1799. doi: 10.1136/ard-2024-226433.
    https://pubmed.ncbi.nlm.nih.gov/39393842/

OCTUBRE 2024

  • Zhang M, Cron RR, Chu N, Nguyen J, Gordon SM, Eloseily EM, Atkinson TP, Weiser P, Walter MR, Kreiger PA, Canna SW, Behrens EM, Cron RQ.
    Role of DOCK8 in cytokine storm syndromes.
    J Allergy Clin Immunol. 2024 Oct 17:S0091-6749(24)01061-3. doi: 10.1016/j.jaci.2024.10.004. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39423879/

SEPTIEMBRE 2024

  • Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F.
    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
    Ann Rheum Dis. 2024 Sep 24:ard-2024-225854. doi: 10.1136/ard-2024-225854. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39317415/

  • Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R, et al.
    Emapalumab Use in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: the REAL-HLH Study.
    Arthritis Rheumatol. 2024 Sep 8. doi: 10.1002/art.42985. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39245963/

AGOSTO 2024

  • Caorsi R, Bertoni A, Matucci-Cerinic C, Natoli V, Palmeri S, Rosina S, Penco F, Malattia C, Consolaro A, Viola S, Papa R, Corcione A, Volpi S, Ravelli A, Gattorno M.
    Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with sJIA and recurrent episodes of MAS.
    Rheumatology (Oxford). 2024 Aug 23:keae440. doi: 10.1093/rheumatology/keae440. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39178016/

  • Behrens EM, de Benedetti F.
    Anti-Interferon-γ Therapy for Cytokine Storm Syndromes.
    Adv Exp Med Biol. 2024;1448:573-582. doi: 10.1007/978-3-031-59815-9_38.
    https://pubmed.ncbi.nlm.nih.gov/39117840/

JULIO 2024

  • Baldo F, Erkens RGA, Mizuta M, Rogani G, Lucioni F, Bracaglia C, et al; PReS MAS/sJIA Working Party and Paediatric Rheumatology International Trial Organization.
    Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.
    Rheumatology (Oxford). 2024 Jul 26:keae391. doi: 10.1093/rheumatology/keae391. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/39058514/

 
JUNIO 2024

  • Lee J, Bae KS, Rhim JW, Lee SY, Jeong DC, Kang JH.
    Macrophage Activation Syndrome in Children: Update on Diagnosis and Treatment.
    Children (Basel). 2024 Jun 21;11(7):755. doi: 10.3390/children11070755.
    https://pubmed.ncbi.nlm.nih.gov/39062205/

MAYO 2024

  • Huang S, Liu Y, Yan W, Zhang T, Wang P, Zhu M, et al.
    Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
    Pediatr Rheumatol Online J. 2024 May 23;22(1):58. doi: 10.1186/s12969-024-00991-3.
    https://pubmed.ncbi.nlm.nih.gov/38783316/

MARZO 2024

  • Ulu K, Aliyev E, Kılıç Könte E, Tanatar A, Türkmen Ş, Doğantan Ş, et al.
    Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
    Rheumatology (Oxford). 2024 Mar 5:keae124. doi: 10.1093/rheumatology/keae124. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38441301/

  • Maeser A, Biernacka-Zielinska M, Smolewska E.
    A MASsive attack: a pediatric case of macrophage activation syndrome complicated by DIC as an onset of systemic juvenile idiopathic arthritis successfully treated with anakinra and review of the literature.
    Rheumatol Int. 2024 Mar 19. doi: 10.1007/s00296-024-05570-z. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38502236/

  • Zhang L, Zhang H, Liu S, Zhang N, Wang Y.
    A less common case of anti-MDA5 and anti-Ro52 antibody-positive juvenile dermatomyositis complicated with macrophage activation syndrome.
    Clin Case Rep. 2024 Mar 20;12(3):e8613. doi: 10.1002/ccr3.8613. 
    https://pubmed.ncbi.nlm.nih.gov/38515992/

  • Zhu D, Chen L, Meng J, Wang M, Ma Y, Chen X, et al.
    Neutrophil activation biomarker pentraxin 3 for diagnosis and monitoring of macrophage activation syndrome occurrence in adult-onset Still's disease
    J Autoimmun. 2024 Mar 8;144:103182. doi: 10.1016/j.jaut.2024.103182. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38460457/

 
ENERO 2024

  • Slaney ED, Modica R, Woolnough L, Kafisheh D, Bell-Brunson DH, Elder M.
    Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with denoviremia.
    Front Pediatr. 2024 Jan 22;11:1336554. doi: 10.3389/fped.2023.1336554.
    https://pubmed.ncbi.nlm.nih.gov/38322244/

  • Zhu D, Ying S, Yang C, Li S, Tang S, Sun C, Fang H, Qiao J.
    Clinical features of macrophage activation syndrome in adult dermatomyositis: A single-center retrospective case-control study.
    Immun Inflamm Dis. 2024 Jan;12(1):e1141. doi: 10.1002/iid3.1141.
    https://pubmed.ncbi.nlm.nih.gov/38270325/

  • Yu JY, Kim TH, Kim YJ, Kang HM, Yoo IH, Rhim JW, Lee SY, Jeong DC.
    Macrophage activation syndrome in neonatal lupus presenting with fever and rash.
    J Rheum Dis. 2024 Jan 1;31(1):49-53. doi: 10.4078/jrd.2023.0039. 
    https://pubmed.ncbi.nlm.nih.gov/38130956/

 
DICIEMBRE 2023

  • Qian Y, Lu M, Zheng Q.
    IL-10 and IFN-γ as markers for early recognition of pediatric systemic lupus erythematosus complicated with macrophage activation syndrome.
    Rheumatology (Oxford). 2023 Dec 18:kead678. doi: 10.1093/rheumatology/kead678. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/38109672/

NOVIEMBRE 2023

  • Batu ED, Sener S, Balık Z, Bayındır Y, Cam V, Kasap Cuceoglu M, Uysal O, Aliyev E, Basaran Ö, Bilginer Y, Özen S.
    Is it possible to predict a disease course prone to macrophage activation syndrome at systemic juvenile idiopathic arthritis diagnosis?
    Clin Rheumatol. 2023 Nov 28. doi: 10.1007/s10067-023-06828-w.
    https://pubmed.ncbi.nlm.nih.gov/38012469/

SEPTIEMBRE 2023

  • Charlesworth JEG, Kavirayani A.
    Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
    Eur J Haematol. 2023 Sep;111(3):458-476. doi: 10.1111/ejh.14029. 
    https://pubmed.ncbi.nlm.nih.gov/37344166/

  • Chang Y, Shan X, Ge Y.
    Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.
    Pediatr Rheumatol Online J. 2023 Sep 21;21(1):106. doi: 10.1186/s12969-023-00893-w.
    https://pubmed.ncbi.nlm.nih.gov/37735702/

 
AGOSTO 2023

  • Gullickson M, Nichols L, Scheibe M.
    A Novel Therapy for a Rare Condition: Continuous Anakinra Infusion for a Patient With Macrophage Activation Syndrome.
    Cureus. 2023 Aug 4;15(8):e42968. doi: 10.7759/cureus.42968.
    https://pubmed.ncbi.nlm.nih.gov/37667692/

JULIO 2023

  • Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M et al.
    The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
    Ann Rheum Dis. 2023 Jul 24:ard-2023-224123. doi: 10.1136/ard-2023-224123. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37487610/

  • Baggio C, Bindoli S, Guidea I, Doria A, Oliviero F, Sfriso P.
    IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome.
    Int J Mol Sci. 2023 Jul 5;24(13):11125. doi: 10.3390/ijms241311125.
    https://pubmed.ncbi.nlm.nih.gov/37446301/

 
MAYO 2023

  • De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert GS, Quartier P, Antón J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C.
    Efficacy and safety of emapalumab in macrophage activation syndrome.
    Ann Rheum Dis. 2023 Jun;82(6):857-865. doi: 10.1136/ard-2022-223739. Epub 2023 Mar 31.
    https://pubmed.ncbi.nlm.nih.gov/37001971/

  • Shimizu M, Nishimura K, Iwata N, Yasumi T, Umebayashi H, Nakagishi Y, et al.
    Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan.
    Int J Rheum Dis. 2023 May;26(5):938-945. doi: 10.1111/1756-185X.14681. Epub 2023 Mar 27.
    https://pubmed.ncbi.nlm.nih.gov/36973039/

 
MARZO 2023

  • De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert GS, Quartier P, Antón J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C.
    Efficacy and safety of Emapalumab in macrophage activation syndrome.
    Ann Rheum Dis. 2023 Mar 31:ard-2022-223739. doi: 10.1136/ard-2022-223739. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/37001971/

  • Kaneko S, Shimizu M, Miyaoka F, Shimbo A, Irabu H, Mizuta M, Nakagishi Y, Iwata N, Fujimura J, Mori M, Morio T.
    The dynamics of laboratory markers reflecting cytokine overproduction in macrophage activation syndrome complicated with systemic juvenile idiopathic arthritis.
    Clin Immunol. 2023 Mar;248:109270. doi: 10.1016/j.clim.2023.109270.
    https://pubmed.ncbi.nlm.nih.gov/36806704/

FEBRERO 2023

  • Zhang HY, Xiao M, Zhou D, Yan F, Zhang Y.
    Platelet and ferritin as early predictive factors for the development of macrophage activation syndrome in children with Kawasaki disease: A retrospective case-control study.
    Front Pediatr. 2023 Feb 15;11:1088525. doi: 10.3389/fped.2023.1088525.
    https://pubmed.ncbi.nlm.nih.gov/36873655/ 

ENERO 2023

  • Bindoli S, Galozzi P, Doria A, Sfriso P.
    Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: A case series.
    Joint Bone Spine. 2023 Jan 6;90(2):105524. doi: 10.1016/j.jbspin.2023.105524. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/36623798/

  • Hiyama T, Kurasawa K, Hasegawa A, Miyao T, Tanaka A, Arai S, et al.
    Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still's disease.
    Clin Exp Med. 2023 Jan 7. doi: 10.1007/s10238-023-00988-4. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/36611087/

 
AGOSTO 2022

  • Levy O, Apel A, Alhdor H, Mizrachi A, Agmon-Levin N, Koren-Michowitz M, Amit-Vazina M.
    Ruxolitinib for Refractory Macrophage Activation Syndrome complicating Adult-Onset Still's Disease
    Eur J Rheumatol. 2022 Aug 9. doi: 10.5152/eurjrheum.2022.21064. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35943464/

  • Rainone M, Ngo D, Baird JH, Budde LE, Htut M, Aldoss I, Pullarkat VA.
    Interferon-γ blockade in CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.
    Blood Adv. 2022 Aug 2:bloodadvances.2022008256. doi: 10.1182/bloodadvances.2022008256. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35917457/

JULIO 2022

  • Kostik MM, Isupova EA, Belozerov K, Likhacheva TS, Suspitsin EN, Raupov R, Masalova VV, Chikova IA, Dubko MF, Kalashnikova OV, Chasnyk VG, Cron RQ.
    Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
    Front Pediatr. 2022 Jul 28;10:894846. doi: 10.3389/fped.2022.894846.
    https://pubmed.ncbi.nlm.nih.gov/35967555/

  • De Matteis A, Colucci M, Rossi MN, Caiello I, Merli P, Tumino N, Bertaina V, Pardeo M, Bracaglia C, Locatelli F, De Benedetti F, Prencipe G.
    Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH.
    Blood. 2022 Jul 21;140(3):262-273. doi: 10.1182/blood.2021013549.
    https://pubmed.ncbi.nlm.nih.gov/35500103/

MAYO 2022

  • Wang R, Li T, Ye S, Lv L, Chen S, Wang X, Bao CD, Fu Q.
    Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
    lin Rheumatol. 2022 May 19. doi: 10.1007/s10067-022-06184-1. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35590113/

  • Ding Y, Ge Y.
    Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome.
    Ther Adv Chronic Dis. 2022 May 13;13:20406223221098128. doi: 10.1177/20406223221098128.
    https://pubmed.ncbi.nlm.nih.gov/35586303/

  • Bossi G, Codazzi AC, Vinci F, Clerici E, Regalbuto C, Crapanzano C, Veraldi D, Moiraghi A, Marseglia GL.
    Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome.
    Children (Basel). 2022 May 5;9(5):672. doi: 10.3390/children9050672.
    https://pubmed.ncbi.nlm.nih.gov/35626849/

 
MARZO 2022

  • Naniwa T, Yamabe T, Ohmura SI, Uehara K, Tamechika SY, Maeda S, Isogai S, Wada J.
    Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment.
    Int J Rheum Dis. 2022 Jun 19. doi: 10.1111/1756-185X.14371. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35719030/

  • Lahiry P, Naumenko S, Couse M, Liao F, Dominguez D, Knight A, Levy DM, Misztal M, Ng LWK, Hiraki LT.
    Hemophagocytic Lymphohistiocytosis Gene Variants in Childhood-Onset SLE with Macrophage Activation Syndrome.
    J Rheumatol. 2022 Jun 1:jrheum.211200. doi: 10.3899/jrheum.211200. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35649546/

 
MARZO 2022

  • Fingerhutová Š, Jančová E, Doležalová P.
    Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
    Front Pediatr. 2022 Mar 7;10:823847. doi: 10.3389/fped.2022.823847
    https://pubmed.ncbi.nlm.nih.gov/35321008/

  • Vagrecha A, Zhang M, Acharya S, Lozinsky S, Singer A, Levine C, Al-Ghafry M, Fein Levy C, Cron RQ.
    Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children.
    Biology (Basel). 2022 Mar 9;11(3):417. doi: 10.3390/biology11030417.
    https://pubmed.ncbi.nlm.nih.gov/35336791/

  • Gartini S, Bougrini Y, Rhazari M, Bourkadi JE.
    Macrophagic activation syndrome revealing disseminated multifocal tuberculosis: A case report of a rare clinical situation.
    Ann Med Surg (Lond). 2022 Mar 9;76:103487. doi: 10.1016/j.amsu.2022.103487.
    https://pubmed.ncbi.nlm.nih.gov/35299938/

 
FEBRERO 2022

  • Mathieu AL, Omarjee O, Walzer T, Belot A.
    Macrophage involvement in juvenile arthritis onset: LACC1 bridges the gap?.
    Med Sci (Paris). 2022 Feb;38(2):133-135. doi: 10.1051/medsci/2021253. Epub 2022 Feb 18.
    https://pubmed.ncbi.nlm.nih.gov/35179464/

 
ENERO 2022

  • AlNouwaiser DN, AlMutairi SS, AlRowailey AS.
    Management of Hepatitis A-induced Macrophage Activation Syndrome With Anakinra in Systemic Juvenile Idiopathic Arthritis: A Case Report.
    Cureus. 2022 Jan 19;14(1):e21430. doi: 10.7759/cureus.21430.
    https://pubmed.ncbi.nlm.nih.gov/35103223/

  • Bindoli S, Giollo A, Galozzi P, Doria A, Sfriso P.
    Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review.
    Exp Biol Med (Maywood). 2022 Jan 22:15353702211070290. doi: 10.1177/15353702211070290.
    https://pubmed.ncbi.nlm.nih.gov/35068221/

 
DICIEMBRE 2021

  • Shimizu M.
    Macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Immunol Med. 2021 Dec;44(4):237-245. doi: 10.1080/25785826.2021.1912893. Epub 2021 May 13.
    https://pubmed.ncbi.nlm.nih.gov/33982649/

NOVIEMBRE 2021

  • Erkens R, Esteban Y, Towe C, Schulert G, Vastert S.
    Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.
    Rheum Dis Clin North Am. 2021 Nov;47(4):585-606. doi: 10.1016/j.rdc.2021.06.003.
    https://pubmed.ncbi.nlm.nih.gov/34635293/

  • Iyengar VV, Chougule A, Gowri V, Taur P, Prabhu S, Bodhanwala M, Desai MM.
    DADA2 presenting as nonimmune hemolytic anemia with recurrent macrophage activation syndrome.
    Pediatr Blood Cancer. 2021 Nov 22:e29461. doi: 10.1002/pbc.29461. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34811889/

 
SEPTIEMBRE 2021

  • Yao H, Wang Y, Wang Z, Zhao J, Deng X, Zhang Z, et al.
    The performance of the diagnostic scoring system or criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis for adult-onset Still's disease. A multicentre case-control study in China.
    Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):129-134. Epub 2021 Sep 30.
    https://pubmed.ncbi.nlm.nih.gov/34596030/

  • Gouda W, Alsaqabi F, Moshrif A, Abbas AS, Abdel-Aziz TM, Islam MA.
    Macrophage activation syndrome triggered by systemic lupus erythematosus flare: successful treatment with a combination of dexamethasone sodium phosphate, intravenous immunoglobulin, and cyclosporine: a case report.
    J Med Case Rep. 2021 Oct 7;15(1):497. doi: 10.1186/s13256-021-03072-1.
    https://pubmed.ncbi.nlm.nih.gov/34620236/

 
AGOSTO 2021

  • Zhang G, Liu W, Zhang X, Liu L.
    Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation: Successful treatment by Tocilizumab.
    Z Rheumatol. 2021 Aug 10. doi: 10.1007/s00393-021-01063-7. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34378080/

  • Reiff DD, Cron RQ.
    Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
    ACR Open Rheumatol. 2021 Aug 25. doi: 10.1002/acr2.11331. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34431626/

JULIO 2021

  • Gao DK, Salomonis N, Henderlight M, Woods C, Thakkar K, Grom AA, Thornton S, Jordan MB, Wikenheiser-Brokamp KA, Schulert GS.
    IFN-gamma is essential for alveolar macrophage driven pulmonary inflammation in macrophage activation syndrome CI Insight. 2021 Jul 27:147593. doi:
    10.1172/jci.insight.147593. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34314387/

  • Ashkenazi L, Hashkes PJ.
    50 Years Ago in The Journal of Pediatrics: Hepatic Dysfunction in Systemic Juvenile Idiopathic Arthritis with Alleviation of Arthritis: The First Description of Macrophage Activation Syndrome?
    J Pediatr. 2021 Jul;234:64. doi: 10.1016/j.jpeds.2021.03.042.
    https://pubmed.ncbi.nlm.nih.gov/34172168/

  

JUNIO 2021

  • Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad.
    Intravenous administration of anakinra in children with macrophage activation syndrome.
    Pediatr Rheumatol Online J. 2021 Jun 29;19(1):98. doi: 10.1186/s12969-021-00585-3.
    https://pubmed.ncbi.nlm.nih.gov/34187503/

 

MAYO 2021

  • Akturk H, Tanyildiz M, Erbey F, Tasdemir M, Celikyurt A, Gonen E, Bilge I.
    Macrophage Activation Syndrome in a Child with Juvenile Idiopathic Arthritis Secondary to SARS-CoV-2.
    J Trop Pediatr. 2021 May 24:fmab049. doi: 10.1093/tropej/fmab049. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34028559/

 

MARZO 2021

  • McGonagle D, Ramanan AV, Bridgewood C.
    Immune cartography of macrophage activation syndrome in the COVID-19 era
    Nat Rev Rheumatol. 2021 Mar;17(3):145-157. doi: 10.1038/s41584-020-00571-1.
    https://pubmed.ncbi.nlm.nih.gov/33547426/

  • Naveen R, Jain A, Muhammed H, Gupta L, Misra DP, Lawrence A, Agarwal V, Misra R, Aggarwal A.
    Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Rheumatol Int. 2021 Mar;41(3):625-631. doi: 10.1007/s00296-020-04763-6.
    https://pubmed.ncbi.nlm.nih.gov/33388903/

  • Yamabe T, Ohmura SI, Uehara K, Naniwa T.
    Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment. A single-center observational study.
    Mod Rheumatol. 2021 Mar 10:1-21. doi: 10.1080/14397595.2021.1899565. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33719871/

  • Paim LB, Landim MLL, Firmino SL, Monteiro CMBE, Cordeiro LR, de Araujo FG, de Carvalho JF.
    Canakinumab for Pulmonary Artery Hypertension and Macrophage Activation Syndrome Associated with Uncontrolled Systemic Juvenile Idiopathic Arthritis.
    Indian J Pediatr. 2021 Mar 20. doi: 10.1007/s12098-021-03734-4. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33742412/

 

FEBRERO 2021 

  • Horne A, von Bahr Greenwood T, Chiang SCC, Meeths M, Björklund C, Ekelund M, Erensjö P, Berg S, Hagelberg S, Bryceson YT, Andersson U, Henter JI.
    Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH).
    J Rheumatol. 2021 Feb 15:jrheum.200941. doi: 10.3899/jrheum.200941.
    https://pubmed.ncbi.nlm.nih.gov/33589555/ 

  • Guo L, Xu Y, Qian X, Zou L, Zheng R, Teng L, Zheng Q, Leung Jung LK, Lu M.J 
    Sudden Hypotension and Increased Serum IFN-gamma and IL-10 Predict Early Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients.
    Pediatr. 2021 Feb 10:S0022-3476(21)00117-7. doi: 10.1016/j.jpeds.2021.02.008. 
    https://pubmed.ncbi.nlm.nih.gov/33581106/ 

  •  Aydın F, Çelikel E, Ekici Tekin Z, Coşkun S, Sezer M, Karagöl C, Kaplan MM, Tekgöz N, Kurt T, Özcan S, Kavurt AV, Özkaya Parlakay A, Çelikel Acar B.
    Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children.
    Int J Rheum Dis. 2021 Feb 7. doi: 10.1111/1756-185X.14078. 
    https://pubmed.ncbi.nlm.nih.gov/33550678/ 

  • Naveen R, Jain A, Muhammed H, Gupta L, Misra DP, Lawrence A, Agarwal V, Misra R, Aggarwal A.
    Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Rheumatol Int. 2021 Mar;41(3):625-631. doi: 10.1007/s00296-020-04763-6. Epub 2021 Jan 2.
    https://pubmed.ncbi.nlm.nih.gov/33388903/

  •  McGonagle D, Ramanan AV, Bridgewood C.
    Immune cartography of macrophage activation syndrome in the COVID-19 era
    Nat Rev Rheumatol. 2021 Mar;17(3):145-157. doi: 10.1038/s41584-020-00571-1.
    https://pubmed.ncbi.nlm.nih.gov/33547426/

 

NOVIEMBRE 2020
  • Sag E, Keskin A, Atalay E, Demir S, Cuceoglu MK, Akca UK, Batu ED, Bilginer Y, Ozen S.
    Performances of the "MS-score" and "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Rheumatol Int. 2020 Nov 19. doi: 10.1007/s00296-020-04750-x.
    https://pubmed.ncbi.nlm.nih.gov/33215249/

 

OCTUBRE 2020
  • Krei JM, Møller HJ, Larsen JB.
    The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.
    Clin Exp Immunol. 2020 Oct 31. doi: 10.1111/cei.13543. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33128796/

 

SEPTIEMBRE 2020
  • Ke Y, Lv C, Xuan W, Wu J, Da Z, Wei H, Zhang M, Tan W.
    Clinical analysis of macrophage activation syndrome in adult rheumatic disease: A multicenter retrospective study.
    Int J Rheum Dis. 2020 Sep 3. doi: 10.1111/1756-185X.13955. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32885598/
  • Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, Conforti A, Carubbi F, Di Cola I, Di Benedetto P, Cipriani P, Grassi D, Masciocchi C, Iagnocco A, Barile A, Giacomelli R.
    Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences.
    Ann Rheum Dis. 2020 Sep;79(9):1152-1155. doi: 10.1136/annrheumdis-2020-218048.
    https://pubmed.ncbi.nlm.nih.gov/32719039/

 

AGOSTO 2020
  • Otsuka R, Seino KI
    Macrophage activation syndrome and COVID-19.
    Inflamm Regen. 2020 Aug 6;40:19. doi: 10.1186/s41232-020-00131-w.
    https://pubmed.ncbi.nlm.nih.gov/32834892/
  • Kübler L, Bittmann I, Kuipers JG.
    Macrophage activation syndrome triggered by active systemic lupus erythematosus: Successful treatment by interleukin-1 inhibition (anakinra)
    Z Rheumatol. 2020 Aug 17. doi: 10.1007/s00393-020-00836-w.
    https://pubmed.ncbi.nlm.nih.gov/32804304/
  • Loomba RS, Villarreal EG, Flores S.
    COVID-19 and Hyperinflammatory Syndrome in Children: Kawasaki Disease with Macrophage Activation Syndrome in Disguise?
    Cureus. 2020 Aug 1;12(8):e9515. doi: 10.7759/cureus.9515.
    https://pubmed.ncbi.nlm.nih.gov/32884871/

 

JULIO 2020
  • Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y, Wada T, Yachie A.
    Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
    Rheumatology (Oxford). 2020 Jul 18:keaa299. doi: 10.1093/rheumatology/keaa299. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32681176/

 

MAYO 2020
  • Pal P, Bose N, Poddar A, Chowdhury K, Saha A.
    Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.
    Clin Rheumatol. 2020 May 17:1–4.
    https://doi.org/10.1007/s10067-020-05133-0

 

MARZO 2020
  • Cron RQ, Chatham WW.
    The Rheumatologist's Role in Covid-19.
    J Rheumatol. 2020 Mar 24. pii: jrheum.200334. doi: 10.3899/jrheum.200334. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32209661
  • Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Pediatr Res. 2020 Mar 17. doi: 10.1038/s41390-020-0843-4. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32184444

 

FEBRERO 2020
  • Alongi A, Naddei R, De Miglio L, Natoli V, Ravelli A.
    Macrophage activation syndrome in pediatrics.Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:13-15. doi: 10.1111/pai.13158.
    https://www.ncbi.nlm.nih.gov/pubmed/32017214

 

ENERO 2020
  • Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H, Okura Y, Kinjo N, Kubota T, Nakagishi Y, Nishimura K, Mohri M, Yashiro M, Yasumura J, Wakiguchi H, Mori M.
    Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2020 Jan 10;18(1):2. doi: 10.1186/s12969-020-0399-1.
    https://www.ncbi.nlm.nih.gov/pubmed/31924225

 

NOVIEMBRE 2019
  • Henderson LA, Cron RQ.
    Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.
    Paediatr Drugs. 2020 Feb;22(1):29-44. doi: 10.1007/s40272-019-00367-1.
    https://www.ncbi.nlm.nih.gov/pubmed/31732958

 

OCTUBRE 2019
  • Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS, Xiao JH, Yu HG, Guo L, Xu YP, Lu MP.
    Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China
    World J Pediatr. 2019 Oct 14. doi: 10.1007/s12519-019-00256-0. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31612427

 

SEPTIEMBRE 2019

  • Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, Beukelman T, Atkinson TP, Cron RQ.
    Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
    Arthritis Rheumatol. 2019 Sep 12. doi: 10.1002/art.41103. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31513353
  • Prencipe G, Bracaglia C, De Benedetti F.
    Interleukin-18 in pediatric rheumatic diseases.
    Curr Opin Rheumatol. 2019 Sep;31(5):421-427. doi:10.1097/BOR.0000000000000634.
    https://www.ncbi.nlm.nih.gov/pubmed/31192813

 

AGOSTO 2019
  • Lind-Holst M, Hartling UB, Christensen AE.
    High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    BMJ Case Rep. 2019 Aug 4;12(8).
    https://www.ncbi.nlm.nih.gov/pubmed/31383678
  • Lin Q, Zhang M, Tang H, Shen Y, Zhu Y, Xu Q, Li X.
    Acute pancreatitis and macrophage activation syndrome in pediatric systemic lupus erythematosus: case-based review.
    Rheumatol Int. 2019 Aug 3. doi: 10.1007/s00296-019-04388-4.
    https://www.ncbi.nlm.nih.gov/pubmed/31377830
  • Takakura M, Shimizu M, Irabu H, Sakumura N, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Clin Immunol. 2019 Aug 23:108252.
    https://www.ncbi.nlm.nih.gov/pubmed/31449879

 

JULIO 2019
  • Minoia F, Bovis F, Davì S, Horne A, Fischbach M, Frosch M, Huber A, Jelusic M, Sawhney S, McCurdy DK, Silva CA, Rigante D, Unsal E, Ruperto N, Martini A, Cron RQ, Ravelli A; PRINTO, CARRA, the PRCSG and the Histiocyte Society.
    Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2019 Jul 11. pii: annrheumdis-2019-215211. doi: 10.1136/annrheumdis-2019-215211. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31296501
  • Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS.
    IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Rheumatology (Oxford). 2019 Jul 20. pii: kez282. doi: 10.1093/rheumatology/kez282. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31326996
  • Mizuta M, Shimizu M, Inoue N, Nakagishi Y, Yachie A.
    Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Cytokine. 2019 Jul;119:182-187.
    https://www.ncbi.nlm.nih.gov/pubmed/30952065

 

FEBRERO 2019
  • Crayne CB, Albeituni S, Nichols KE, Cron RQ.
    The Immunology of Macrophage Activation Syndrome.
    Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119. eCollection 2019.
    https://www.ncbi.nlm.nih.gov/pubmed/30774631

 

SEPTIEMBRE 2018
  • Yasin S, Schulert GS.
    Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
    Curr Opin Rheumatol. 2018 Sep;30(5):514-520
    https://www.ncbi.nlm.nih.gov/pubmed/29870499

 

AGOSTO 2018
  • Lerkvaleekul B, Vilaiyuk S.
    Macrophage activation syndrome: early diagnosis is key.
    Open Access Rheumatol. 2018 Aug 31;10:117-128. doi: 10.2147/OARRR.S151013. eCollection 2018.
    https://www.ncbi.nlm.nih.gov/pubmed/30214327

 

ABRIL 2018
  • Sönmez HE, Demir S, Bilginer Y, Özen S.
    Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
    Clin Rheumatol. 2018 Apr 16. doi: 10.1007/s10067-018-4095-1. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29663156
  • Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM, Thomson W, Kastner DL, Woo P, Ombrello MJ
    IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Apr 2. doi: 10.1002/art.40498. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29609200

 

FEBRERO 2018

 

ENERO 2018
  • Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT.
    Features, Treatment and Outcomes of Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus.
    Arthritis Rheumatol. 2018 Jan 17. doi: 10.1002/art.40417. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29342508
  • Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, Kostik M, Lovell D, Maritsi D, Nigrovic PA, Pal P, Ravelli A, Shimizu M, Stanevicha V, Vastert S, Woerner A, de Benedetti F, Grom AA.
    Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation SyndromeAssociated With Systemic Juvenile Idiopathic Arthritis.
    Arthritis Care Res (Hoboken). 2017 May 12. doi: 10.1002/acr.23277. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28499329

 

DICIEMBRE 2017
  • Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, Carubbi F, Di Battista C, Verrotti A, Giacomelli R.
    Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.
    Clin Rheumatol. 2017 Dec;36(12):2839-2845.
    https://www.ncbi.nlm.nih.gov/pubmed/28914368
  • Shimizu M, Mizuta M, Yasumi T, Iwata N, Okura Y, Kinjo N, Umebayashi H, Kubota T, Nakagishi Y, Nishimura K, Yashiro M, Yasumura J, Yamazaki K, Wakiguchi H, Okamoto N, Mori M.
    Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis.
    Arthritis Care Res (Hoboken). 2017 Dec 1. doi: 10.1002/acr.23482. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29195002https://www.ncbi.nlm.nih.gov/pubmed/29195002
  • Núñez Cuadros E, Cabrera Del Moral A, Jiménez Hinojosa JM, Leiva Gea I, Conejo Muñoz L.
    [Haemophagocytic syndrome secondary to endocarditis due to Bartonella henselae].
    An Pediatr (Barc). 2017 Dec 7. pii: S1695-4033(17)30450-2. doi: 10.1016/j.anpedi.2017.11.004. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29233492

 

NOVIEMBRE 2017
  • Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O, Ciccia F, Guggino G, Triolo G, Giacomelli R.
    Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?
    Expert Rev Clin Immunol. 2017 Nov;13(11):1041-1047
    https://www.ncbi.nlm.nih.gov/pubmed/28837367

 

OCTUBRE 2017
  • Grom AA.
    Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation.
    J Pediatr. 2017 Oct;189:19-21.e1. doi: 10.1016/j.jpeds.2017.07.025.
    https://www.ncbi.nlm.nih.gov/pubmed/28838727
  • Minoia F, Bovis F, Davì S, Insalaco A, Lehmberg K, Shenoi S, et al.
    Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.
    J Pediatr. 2017 Oct;189:72-78.e3. doi: 10.1016/j.jpeds.2017.06.005.
    https://www.ncbi.nlm.nih.gov/pubmed/28807357

 

AGOSTO 2017
  • Grom AA.
    Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation.
    J Pediatr. 2017 Aug 21. pii: S0022-3476(17)30959-9. doi: 10.1016/j.jpeds.2017.07.025. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28838727
  • Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Clin Exp Immunol. 2017 Aug 16. doi: 10.1111/cei.13026. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28815559
  • Minoia F, Bovis F, Davì S, Insalaco A, Lehmberg K, Shenoi S, Weitzman S, Espada G, Gao YJ, Anton J, Kitoh T, Kasapcopur O, Sanner H, Merino R, Astigarraga I15, Alessio M, Jeng M, Chasnyk V, Nichols KE, Huasong Z, Li C, Micalizzi C, Ruperto N, Martini A, Cron RQ, Ravelli A, Horne A; Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.
    Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.
    J Pediatr. 2017 Aug 11. pii: S0022-3476(17)30783-7. doi: 10.1016/j.jpeds.2017.06.005. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28807357
  • Huang R, Hayashi Y, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang, Jordan MB, Li Y, Huang G
    HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis.
    Haematologica. 2017 Aug 31. pii: haematol.2017.174979. doi: 10.3324/haematol.2017.174979. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28860338

 

JUNIO 2017

 

MAYO 2017

 

ABRIL 2017
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease
    J Rheumatol. 2017 Apr 15. pii: jrheum.161286. doi: 10.3899/jrheum.161286. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28412707
  • Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, Zeng XZ, Wang Z, Zhao JX, Liu XY, Zhu J, Zhao Y, Zeng XF, Li ZG.
    Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China
    Clin Rheumatol. 2017 Apr 13. doi: 10.1007/s10067-017-3625-6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28409239 

 

MAYO 2017

 

ABRIL 2017
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease
    J Rheumatol. 2017 Apr 15. pii: jrheum.161286. doi: 10.3899/jrheum.161286. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28412707
  • Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, Zeng XZ, Wang Z, Zhao JX, Liu XY, Zhu J, Zhao Y, Zeng XF, Li ZG.
    Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China
    Clin Rheumatol. 2017 Apr 13. doi: 10.1007/s10067-017-3625-6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28409239

 

MARZO 2017
  • Shi L, Hu F, Xu C, Zhu H, Qie D, Yuan C, Tao Y, Liu H.
    Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with combined pneumonia.
    Int J Rheum Dis. 2017 Mar 22. doi: 10.1111/1756-185X.13064.
    https://www.ncbi.nlm.nih.gov/pubmed/28328098
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome.
    Semin Arthritis Rheum. 2017 Feb 8. pii: S0049-0172(16)30373-0. doi: 10.1016/j.semarthrit.2017.02.002. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28268026

 

FEBRERO 2017

 

ENERO 2017
  • Bracaglia C, Prencipe G, De Benedetti F.
    Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.
    Pediatr Rheumatol Online J. 2017 Jan 17;15(1):5. doi: 10.1186/s12969-016-0130-4.
    https://www.ncbi.nlm.nih.gov/pubmed/28095869

 

DICIEMBRE 2016
  • Palman J, May J, Pilkington C.
    Macrophage activation syndrome triggered by coeliac disease: a unique case report.
    Pediatr Rheumatol Online J. 2016 Dec 9;14(1):66.
    https://www.ncbi.nlm.nih.gov/pubmed/27938384
  • Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.
    Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2017 Jan;76(1):166-172.
    https://www.ncbi.nlm.nih.gov/pubmed/27296321

 

NOVIEMBRE 2016
  • García-Montoya L, Sáenz-Tenorio CN, Janta I, Menárguez J, López-Longo FJ, Monteagudo I, Naredo E.
    Hemophagocytic lymphohistiocytosis in a patient with Sjögren's syndrome: case report and review.
    Rheumatol Int. 2016 Nov 16.
    https://www.ncbi.nlm.nih.gov/pubmed/27853859

 

OCTUBRE 2016
  • Aytaç S, Batu ED, Ünal Ş, Bilginer Y, Çetin M, Tuncer M, Gümrük F, Özen S.
    Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus
    Rheumatol Int. 2016 Oct;36(10):1421-9
    https://www.ncbi.nlm.nih.gov/pubmed/27510530

 

SEPTIEMBRE 2016
  • Hernández-Jiménez P,Díaz-Pedroche C, Laureiro J, Madrid O, Martín E, Lumbreras C.
    Hemophagocytic lymphohistiocytosis: Analysis of 18 cases.
    Med Clin (Barc). 2016 Oct 7.
    https://www.ncbi.nlm.nih.gov/pubmed/27726848
  • Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC.
    A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.
    JCI Insight. 2016 Sep 22;1(15):e88181.
    https://www.ncbi.nlm.nih.gov/pubmed/27699249
  • Thomas W, Veer MV, Besser M.
    Haemophagocytic lymphohistiocytosis: an elusive syndrome.
    Clin Med (Lond). 2016 Oct;16(5):432-436.
    https://www.ncbi.nlm.nih.gov/pubmed/27697804
  • Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, Berardicurti O, Guggino G, Di Benedetto P, Di Bartolomeo S, Valenti M, Triolo G,  Giacomelli R.
    Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers.
    Autoimmun Rev. 2016 Sep 21. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/27664384
  • Crayne CB, Khatami KS, Galliano G.
    Macrophage Activation Syndrome.
    Clin Pediatr (Phila). 2016 Oct;55(11):1001-4.
    https://www.ncbi.nlm.nih.gov/pubmed/27562237

 

AGOSTO 2016
  • Aytaç S, Batu ED, Ünal Ş, Bilginer Y, Çetin M, Tuncer M, Gümrük F, Özen S.
    Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Rheumatol Int. 2016 Oct;36(10):1421-9.
    http://www.ncbi.nlm.nih.gov/pubmed/27510530
  • Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.
    Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2016 Jun 13. pii: annrheumdis-2015-209020. doi: 10.1136/annrheumdis-2015-209020. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27296321

 

JUNIO 2016
  • Gormezano NW, Otsuzi CI, Barros DL, da Silva MA, Pereira RM, Campos LM, Borba EF, Bonfá E, Silva CA.
    Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients.
    Semin Arthritis Rheum. 2016 Jun;45(6):706-10. doi: 10.1016/j.semarthrit.2015.10.015
    http://www.ncbi.nlm.nih.gov/pubmed/26833399

 

MARZO 2016
  • Grom AA, Horne A, De Benedetti F.
    Macrophage activation syndrome in the era of biologic therapy.
    Nat Rev Rheumatol. 2016 Mar 24. doi: 10.1038/nrrheum.2015.179. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27009539

 

FEBRERO 2016
  • Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, Proost P, Fallarino F, Wouters CH, Matthys P.
    IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    PLoS One. 2016 Feb 25;11(2):e0150075. doi: 10.1371/journal.pone.0150075. eCollection 2016.
    http://www.ncbi.nlm.nih.gov/pubmed/26914138
  • Tasaki Y, Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Wada T, Yachie A.
    Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
    Cytokine. 2016 Feb 20;80:1-6. doi: 10.1016/j.cyto.2016.02.008. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26908294

 

ENERO 2016
  • Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Leon K, Lheritier K, Abrams K.
    Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
    Arthritis Rheumatol. 2016 Jan;68(1):218-28. doi: 10.1002/art.39407.
    http://onlinelibrary.wiley.com/doi/10.1002/art.39407/abstract

 

DICIEMBRE 2015
  • Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ
    Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2015 Dec 3;13(1):55. doi: 10.1186/s12969-015-0055-3.
    http://www.ncbi.nlm.nih.gov/pubmed/26634252

 

OCTUBRE 2015
  • Ravelli A, Davì S, Minoia F, Martini A, Cron RQ.
    Macrophage Activation Syndrome
    Hematol Oncol Clin North Am. 2015 Oct;29(5):927-41.
    http://www.ncbi.nlm.nih.gov/pubmed/26461152
  • Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovich L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnick-Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Pediatric Rheumatology International Trials Organization; Childhood Arthritis & Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society.
    Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Arthritis Rheumatol. 2015 Aug 28. doi: 10.1002/art.39332. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26314788
  • Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Leon K, Lheritier K, Abrams K.
    Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome.
    Arthritis Rheumatol. 2015 Aug 28. doi: 10.1002/art.39407. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26314396 

 

AGOSTO 2015
  • Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R.
    Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome.
    Arthritis Rheumatol. 2015 Aug 5. doi: 10.1002/art.39295. EPUB ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26251193

 

JULIO 2015
  • Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, Kubota T, Yamasaki Y, Takei S, Yachie A
     Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Clin Immunol. 2015 Jun 20;160(2):277-281. doi: 10.1016/j.clim.2015.06.005. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26101092

 

JUNIO 2015
  • Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; and the Histiocyte Society.
    Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol June 2015 42(6):994-1001, doi:10.3899/jrheum.141261
    http://www.ncbi.nlm.nih.gov/pubmed/25877504

 

ABRIL 2015
  • Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; and the Histiocyte Society.
    issecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2015 Apr 15. pii: jrheum.141261. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25877504  
  • Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L.
    Macrophage activation syndrome in the course of monogenic autoinflammatory disorders.
    Clin Rheumatol. 2015 Apr 8. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25846831

 

MARZO 2015
  • Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C, Fallarino F, De Somer L, Tousseyn T, Quartier P, Wouters C, Matthys P.
    Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Rheumatology (Oxford). 2015 Mar 12. pii: keu524. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25767156

 

FEBRERO 2015
  • Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S.
    Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    J Rheumatol. 2015 Feb 15.
    http://www.ncbi.nlm.nih.gov/pubmed/25684767

 

SEPTIEMBRE 2014
  • Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G.
    Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome (HScore).
    Arthritis Rheumatol. 2014 Sep; 66(9):2613-2620.
    http://www.ncbi.nlm.nih.gov/pubmed/24782338

 

JULIO 2014
  • Davì S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, Bovis F et al on behalf of the Pediatric Rheumatology International Trials Organization; the Childhood Arthritis & Rheumatology Research Alliance; the Pediatric Rheumatology Collaborative Study Group; the Histiocyte Society.
    Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Arthritis Rheumatol. 2014 Jul 7. doi: 10.1002/art.38769. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25044674
  • Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, Filipovich A, Fall N, Harley JB, Nirmala NR, Grom AA.
    Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis.
    Arthritis Rheumatol. 2014 Jul 21. doi: 10.1002/art.38793. [Epub ahead of print].
    http://www.ncbi.nlm.nih.gov/pubmed/25047945
  • Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C et al on behalf of the Pediatric Rheumatology International Trials Organization; the Childhood Arthritis& Rheumatology Research Alliance; the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.
    Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A multinational, multicenter study of 362 patients.
    Arthritis Rheumatol. 2014 Jul 30. doi: 10.1002/art.38802.
    http://www.ncbi.nlm.nih.gov/pubmed/25077692

 

MAYO 2014
  • Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL.
    A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: A challenging clinical case in light of the current diagnostic criteria.
    Autoimmun Rev. 2014 May 29. pii: S1568-9972(14)00128-1. doi: 10.1016/j.autrev.2014.05.009. [Epub ahead of print].
    http://www.ncbi.nlm.nih.gov/pubmed/24879966

 

ENERO 2014
  • Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A.
    Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Int J Rheum Dis. 2014 Jan 13. doi: 10.1111/1756-185X.12196. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24417800

 

JUNIO 2013
  • Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G.
    Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.
    J Pediatr. 2013 Jun;162(6):1245-51. doi: 10.1016/j.jpeds.2012.11.081. Epub 2013 Jan 17.
    http://www.ncbi.nlm.nih.gov/pubmed/23333131

 

MAYO 2013
  • Kahn PJ,Cron RQ
    Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome.
    J Rheumatol 2013 May;40(5):743-4. doi: 10.3899/jrheum.121098.
    http://www.ncbi.nlm.nih.gov/pubmed/23637382

 
Última actualización: 9 enero 2025
 
SOCIEDADES
CONGRESOS
Pediatric Rheumatology European Society PReS 2026
16 a 19 de Septiembre de 2026, Belgrado, Serbia
presGenerico
Pres2026
   
EULAR EULAR 2026
3 a 6 de junio de 2026, Londres, Reino Unido
eular  eular 2026
 
American College of Rheumatology ACR 2026
6 a 11 de noviembre de 2026, Orlando, Florida, EEUU
American College of Rheumatology 

ACR2026
https://rheumatology.org/annual-meeting
Asociación Española de Pediatría AEP 2026
11 a 13 de junio de 2026.  San Sebastián
aep AEP 2026  
Sociedad Española de Reumatología SER 2026
5 a  8 de mayo de 2026, Bilbao
ser ser 2026
 
Sociedad Española Multidisciplinar de
Enfermedades Autoinmunes Sistémicas
 SEMAIS 2025
SEMAIS HORIZONTAL 1

https://semais.es/
 
SOCIEDAD
Pediatric Rheumatology International Trials Organization
 printo printo2
Última actualización: 18 noviembre 2025
 
 
Última actualización: 03 Abril 2019
Hemos leído...
 
 
FEBRERO 2019
  • Neely J, Long CS, Sturrock H, Kim S; CARRA Registry Investigators.
    The Association of Short-term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis.
    Arthritis Care Res (Hoboken). 2019 Feb 4. doi: 10.1002/acr.23840.
    https://www.ncbi.nlm.nih.gov/pubmed/30714338
  • Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, Bughin V, Jouen F, Musset L, Allenbach Y, Hachulla E, Maillard H, Meyer A12, Bourrat E, Benveniste O; French Network of rare autoimmune, autoinflammatory diseases FAI2R.
    French expert opinion for the management of juvenile dermatomyositis.
    Arch Pediatr. 2019 Feb;26(2):120-125. doi: 10.1016/j.arcped.2018.12.002. Epub 2019 Jan 10.
    https://www.ncbi.nlm.nih.gov/pubmed/30638764
 
DICIEMBRE 2014
JULIO 2014
  • Rheumatology (Oxford). 2014 Jul 4. pii: keu256. [Epub ahead of print]In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
    Schwartz T1, Sjaastad I2, Flatø B3, Vistnes M3, Christensen G4, Sanner H5.
    http://www.ncbi.nlm.nih.gov/pubmed/24996906
  • G Ital Dermatol Venereol. 2014 Jul 18.
    An update on juvenile dermatomyositis.
    Boccaletti V1, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C.
    http://www.ncbi.nlm.nih.gov/pubmed/25034096
  • Clin Rheumatol. 2014 Jul 23.
    Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
    Singh S1, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
    http://www.ncbi.nlm.nih.gov/pubmed/25053380
  • J Microbiol Immunol Infect. 2014 Jul 25.
    Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
    Yu HH1, Chang HM2, Chiu CJ3, Yang YH1, Lee JH1, Wang LC1, Lin YT1, Chiang BL4.
    http://www.ncbi.nlm.nih.gov/pubmed/25070283
  • Pediatr Rheumatol Online J. 2014 Jul 21;12:31. doi: 10.1186/1546-0096-12-31. eCollection 2014.
    Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.
    McCann LJ1, Arnold K2, Pilkington CA3, Huber AM4, Ravelli A5, Beard L2, Beresford MW6, Wedderburn LR7.
    http://www.ncbi.nlm.nih.gov/pubmed/25075205
  • Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
    http://www.ncbi.nlm.nih.gov/pubmed/24987158
  • Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
    http://www.ncbi.nlm.nih.gov/pubmed/24989778
  • Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
    Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24987158
  • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
    Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24989778
JUNIO 2014
  • Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T.
    Prognostic factors for myositis-associated interstitial lung disease
    PLoS One. 2014 Jun 6;9(6):e98824. doi: 10.1371/journal.pone.0098824. eCollection 2014.
    http://www.ncbi.nlm.nih.gov/pubmed/24905449
  • Neri R, Barsotti S, Iacopetti V, Tripoli A, dʼAscanio A, Tavoni AG, Mosca M, Bombardieri S.
    Clinically amyopathic dermatomyositis: analysis of a monocentric cohort.
    J Clin Neuromuscul Dis. 2014 Jun;15(4):157-60. doi: 10.1097/CND.0000000000000038.
    http://www.ncbi.nlm.nih.gov/pubmed/24872214
MAYO2014
  • Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.
    Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis.
    JAMA Dermatol. 2014 May 28. doi: 10.1001/jamadermatol.2013.10416. [Epub ahead of print]
  • Rev Med Interne. 2014 May 21.[Epub ahead of print] Lung is also involved in juvenile dermatomyositis.
    Article in French
    Pouessel G1, Thumerelle C2, Nève V3, Santangelo T4, Flammarion S1, Pruvot I5, Tillie-Leblond I6, Deschildre A7.
    http://www.ncbi.nlm.nih.gov/pubmed/24856457
MARZO 2014
  • Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10. doi: 10.1002/acr.22142.
    Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry.
    Robinson AB1, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators.
    http://www.ncbi.nlm.nih.gov/pubmed/23983017
  • Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.
    Predictors of clinical improvement in rituximab-treated refractory adult
    and juvenile dermatomyositis and adult polymyositis.
    Aggarwal R1, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.
    http://www.ncbi.nlm.nih.gov/pubmed/24574235
FEBRERO 2014
  • J Med Case Rep. 2014 Feb 15;8(1):54. [Epub ahead of print] Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report.
    McCrea N, Al-Sabbagh A, Ahmed S, Walker D, Rangaraj S.
    http://www.ncbi.nlm.nih.gov/pubmed/24529167


Más artículos...

PATROCINADORES
kisspng-logo-novartis-healthcare-private-limited-brand-nov-zpsob-platby-ix-bilaterln-esko-slovensk-5b68603aa47fe12537627915335670346738 sobi